Up next

Autoplay

Common side-effects of BTK inhibitors (ibrutinib and acalabrutinib) in the treatment of CLL

1 Views • 08/29/25
Share
Side Effects
Side Effects
Subscribers
0

Peter Hillmen, MBChB, PhD from St. James' University Hospital, Leeds, UK, explains how Bruton's tyrosine kinase inhibitors, like ibrutinib and acalabrutinib (ACP-196), target chronic lymphocytic leukemia (CLL) cells and the common side-effects experienced by these drugs.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.

Show more
0 Comments sort Sort By

Up next

Autoplay